GaldermaReceivesU.S.FDAApprovalforRestylaneLyftfortheEnhancementoftheChinProfile
===2025/11/5 21:22:08===
tive, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:www.galderma.com.
References
Galderma. Data on file. MA-60800. 43USCH2208 R Lyft Chin US Clinical Study Report.
Restylane®Lyft. Instructions for Use. Availableonline. Galderma Laboratories, L.P., 2025.
Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
Galderma. Data on file. MA-55607. Restylane®27 years dat
=*=*=*=*=*=
当前为第9/13页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页